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Natural killer (NK) cells possess potent cytotoxic
mechanisms that need to be tightly controlled.
Here, we explored the regulation and function of
GPR56/ADGRG1, an adhesion G protein-coupled re-
ceptor implicated in developmental processes and
expressed distinctively in mature NK cells. Expres-
sion of GPR56 was triggered by Hobit (a homolog
of Blimp-1 in T cells) and declined upon cell
activation. Through studying NK cells from polymi-
crogyria patients with disease-causing mutations in
ADGRG1, encoding GPR56, and NK-92 cells ectopi-
cally expressing the receptor, we found that GPR56
negatively regulates immediate effector functions,
including production of inflammatory cytokines and
cytolytic proteins, degranulation, and target cell
killing. GPR56 pursues this activity by associating
with the tetraspanin CD81. We conclude that
GPR56 inhibits natural cytotoxicity of human NK
cells.INTRODUCTION
Natural killer (NK) cells are innate lymphoid cells that develop,
mainly in the bone marrow, through a series of distinct pheno-
typic stages before they enter the circulation to specifically erad-
icate virus-infected and transformed cells (Freud and Caligiuri,Cel
This is an open access article under the CC BY-N2006). Upon target cell encounter, differentiated CD56dim NK
cells produce large amounts of cytokines, chemokines, and
cytolytic proteins, similar to effector-type CD8+ T cells (Fauriat
et al., 2010; Nagler et al., 1989; Vivier et al., 2008). The activity
of cytotoxic CD56dim NK and CD8+ T cells is regulated by a
comprehensive repertoire of activating and inhibitory receptors,
including immunoglobulin-like receptors and C-type lectins (La-
nier, 2008; Pegram et al., 2011).
G protein-coupled receptors (GPCRs) guide numerous cellular
processes, including development and differentiation (Pierce
et al., 2002); yet, in the immune system, they have been linked
primarily with chemotaxis (Walzer and Vivier, 2011). We, and
others, recently showed that human cytotoxic lymphocytes,
including CD56dim NK cells andCD27CD45RA+ T cells, express
the adhesion family GPCR (aGPCR) GPR56/ADGRG1 (Della
Chiesa et al., 2010; Peng et al., 2011). Expression of GPR56
correlated closely with production of the cytolytic proteins per-
forin, granzyme A, and granzyme B and was not found in non-
cytotoxic lymphocytes or myeloid cells.
aGPCRs possess an N-terminal fragment (NTF) and aC-termi-
nal fragment (CTF) that arise from autocatalytic cleavage at a
GPCR-proteolytic site (GPS), embedded in a juxtamembranous
GPCR autoproteolysis-inducing (GAIN) domain (Arac¸ et al.,
2012; Lin et al., 2004). At the cell surface, the NTF remains
non-covalently attached to the CTF, giving rise to a character-
istic bipartite structure with the two fragments being engaged
in distinct activities (Langenhan et al., 2013). The NTF of
GPR56 binds transglutaminase and collagen III, while the CTF
recruits Ga proteins, leading to activation of RhoA (Ras homolog
gene family member A) and mTOR (mechanistic target ofl Reports 15, 1757–1770, May 24, 2016 ª 2016 The Author(s) 1757
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rapamycin) pathways (Ackerman et al., 2015; Giera et al., 2015;
Iguchi et al., 2008; Little et al., 2004; Luo et al., 2011; Paavola
et al., 2011; Stoveken et al., 2015; White et al., 2014; Xu et al.,
2006).
Here, we tested the relation of GPR56 with the differentiation,
activation, and function of human NK cells. We provide evidence
that GPR56 expression is triggered by the transcriptional
repressor Hobit (homolog of Blimp-1 in T cells), is downregulated
upon cellular activation, and inhibits immediate effector func-
tions, including inflammatory cytokine and cytolytic protein pro-
duction, degranulation, and target cell killing. We conclude that
GPR56 is a differentiation marker and inhibitory receptor on hu-
man NK cells.
RESULTS
Hobit Drives Expression of GPR56 in Non-dividing, Fully
Differentiated Human NK Cells
GPR56 is expressed by all human cytotoxic lymphocytes,
including CD56dim NK cells (Della Chiesa et al., 2010; Peng
et al., 2011). Upon stimulation with common gamma chain cyto-
kines, such as interleukin (IL)-2, proliferating NK cells lose
expression of GPR56 (Della Chiesa et al., 2010) (Figure 1A).
IL-2-dependent cytotoxic NK-92 cells weakly express GPR56.
IL-2withdrawal stoppedNK-92 cell division, leading to cell-cycle
arrest in the G1 phase and surface expression of GPR56 (Fig-
ure 1B). Of note, IL-2 deprivation caused the upregulation of
surface markers commonly associated with terminal cell differ-
entiation—such as KLRG1 (killer cell lectin-like receptor subfam-
ily Gmember 1) andB3GAT1 (galactosylgalactosylxylosylprotein
3-beta-glucuronosyltransferase 1), the enzyme that generates
the CD57 glycosylation epitope—and the downregulation of
the cell exhaustion marker PD1 (programmed cell death 1) (Fig-
ure 1C). These changes correlated with the altered expression of
transcription factors involved in effector lymphocyte develop-
ment, such as Blimp-1 (B lymphocyte-induced maturation pro-
tein-1), Bcl-6 (B cell lymphoma 6), T-bet (T-box expressed in
T cells), Eomes (eomesodermin), and the recently identified Ho-
bit (van Gisbergen et al., 2012; Vieira Braga et al., 2015) (Fig-
ure 1C). In line with their in-part contrary activities (Crotty et al.,Figure 1. Hobit Drives the Expression of GPR56 in Non-dividing, Fully
(A) Expression of GPR56 on proliferating CD56+CD3– NK cells was measured us
plots of one representative experiment (left) and quantification of the mean perc
(B) NK-92 cells were incubated with or without 50 U/ml IL-2 for 18 hr and analyzed
percentages of cells in G1, S, and G2/M phases and relative geometric mean fluor
(right).
(C) Quantification of mRNA expression of surface molecules and transcription fac
(D) Protein expression of surfacemolecules and transcription factors by CD56+CD
measured by flow cytometry.
(E) Expression of GPR56 on long-lived memory-like NK cells, defined by absent/
(F–H) NK-92 cells overexpressing scrambled shRNA, Eomes shRNA, or Hobit shR
cytometry for expression of Eomes, Hobit, and GPR56. Representative flow cytom
to isotype controls, by flow cytometry (G); and quantification of mRNA expressio
(I–K) Parental Jurkat cells and Jurkat cells overexpressing vector control or FLAG-
by flow cytometry for expression of FLAG and GPR56. Representative flow cytom
to isotype controls, by flow cytometry (J); and quantification of mRNA expressio
All data are means ± SEM of three to five independent experiments. *p < 0.05; *
See also Figure S1.2010; Daussy et al., 2014; Knox et al., 2014), downregulation
of Blimp-1 and T-bet was accompanied by the upregulation of
Bcl-6 and Eomes, respectively. The most prominent change,
with an 25-fold induction, occurred with Hobit.
Next, we correlated GPR56 protein expression with the pres-
ence of various surface molecules, cytolytic proteins, and tran-
scription factors in primary NK cells. In line with its absence on
immature CD56high NK cells, we detected almost no GPR56 on
NK cells from tonsil (data not shown). In contrast, mature circu-
lating NK cells commonly expressed GPR56. GPR56 was ac-
quired prior to the late differentiation/senescence markers
KLRG1 and CD57 (Bjo¨rkstro¨m et al., 2010; Lopez-Verge`s et al.,
2010), as most clearly exemplified by cells from cord blood (Fig-
ure 1D). In line with the uniform presence of GPR56 on CD56dim
NK cells, no association was found with the expression of acti-
vating or inhibitory natural cytotoxicity receptors (NKp30,
NKp44, and NKp46), NK-cell receptors (NKG2a, NKG2c, and
NKG2d), and killer immunoglobulin-like receptors (KIR2DL1/
S1, KIR2DL2/L3, and KIR3DL1) (Figure S1). Supporting previous
findings (Peng et al., 2011), the presence of GPR56 correlated
with production of the cytolytic mediators perforin and granzyme
B (Figure S1). Cells expressing GPR56 were positive for the tran-
scription factors T-bet, Eomes, and Hobit; in particular, expres-
sion of GPR56 and Hobit was strongly associated (Figure 1D).
Thus, non-dividing, fully differentiated NK cells, found in the cir-
culation and commonly identified as CD56dim cells, express
GPR56 in a distinctive manner.
Recent studies identified a subset of long-lived memory-like
NK cells, associated with prior human cytomegalovirus infection,
that can mount long-term effective recall responses (Lee et al.,
2015; Schlums et al., 2015; Zhang et al., 2013). We found that
these memory-like NK cells, which can be distinguished by low
expression of the transcription factor PLZF (promyelocytic leu-
kemia zinc finger) and lack of FcRg (high-affinity immunoglobulin
[Ig]E receptor, g subunit), express GPR56 (Figure 1E).
The T-box transcription factor Eomes is crucially involved in
effector lymphocyte differentiation and, like GPR56, is ex-
pressed in differentiating neurons in the developing human brain
(Elsen et al., 2013). Intriguingly, lack of Eomes causes a micro-
cephaly syndrome (Baala et al., 2007) similar to themalformationDifferentiated NK Cells
ing CFSE dilution after 6 days of stimulation with 50 U/ml IL-2. Flow cytometry
entage of proliferating cells (right).
for cell cycle and expression of GPR56 by flow cytometry (left). Quantification of
escence intensity (geoMFI) of GPR56 expression, compared to isotype controls
tors by RT-PCR in NK-92 cells, incubated with or without 50 U/ml IL-2 for 18 hr.
3NK cells in cord blood and peripheral blood in relation to GPR56 expression,
low expression of FcRg and PLZF, determined by flow cytometry.
NA were incubated with or without 50 U/ml IL-2 for 18 hr and analyzed by flow
etry plots (F); quantification of Hobit andGPR56 protein expression, compared
n of GPR56 by RT-PCR (H).
tagged Hobit were incubated with 10 mg/ml doxycycline for 48 hr and analyzed
etry plots (I); quantification of FLAG and GPR56 protein expression, compared
n of Hobit and GPR56 by RT-PCR (K).
*p < 0.01; ***p < 0.005.
Cell Reports 15, 1757–1770, May 24, 2016 1759
AB
C
Figure 2. Normal Development and Functional Competence of NK
Cells in BFPP Patients
Shown are data of two Dutch siblings with the R565W mutation and age-
matched healthy control donors.
(A) Quantification of the percentage of NK cells among circulating lymphocytes
and the expression of surface molecules, cytolytic proteins, and transcription
factors by CD56dimCD3 NK cells, measured by flow cytometry.
1760 Cell Reports 15, 1757–1770, May 24, 2016seen in patientswith null GPR56 expression (Piao et al., 2004). To
test a causal relationship between Eomes and the expression of
GPR56, we applied short hairpin RNA (shRNA) knockdown of
EOMES in NK-92 cells. Reduced Eomes expression did not pre-
vent GPR56 induction upon IL-2 withdrawal (Figure 1F). In
contrast, knockdown of ZNF683, encoding Hobit, largely pre-
vented GPR56 induction in NK-92 cells cultured without IL-2
(Figures 1F–1H). Furthermore, ectopic expression of Hobit in
Jurkat cells, which express neither GPR56 nor Hobit, induced
expression of GPR56 (Figures 1I–1K), indicating that Hobit drives
the expression of GPR56 in human lymphocytes.
GPR56 Deficiency Does Not Affect NK-Cell
Development but Correlates with Elevated NK-Cell
Functions
Loss-of-function mutations in ADGRG1, encoding GPR56,
cause a severe cortical malformation known as bilateral fronto-
parietal polymicrogyria (BFPP) (Piao et al., 2004, 2005). To test
whether defective expression of GPR56 would affect NK-cell dif-
ferentiation and/or function, we studied two unrelated pairs of
BFPP siblings bearing the mutations 1693C > T (R565W) and
1036T > A (C346S), respectively. Previous in vitro analysis re-
vealed that both mutations strongly reduce the surface expres-
sion of GPR56 (Chiang et al., 2011; Jin et al., 2007). We found
that the R565W mutation abolished GPR56 expression on NK
(and T) cells completely, whereas the C346S mutation reduced
surface levels of GPR56 by about 20-fold (Figure 2A; Figure S2).
All patients had normal numbers of circulating NK cells (Fig-
ure 2A; Figure S2C). Moreover, their NK cells had a fairly normal
phenotype, based on the expression of surface molecules,
including receptors with activating or inhibiting effector func-
tions, cytolytic proteins, and transcription factors (Figure 2A; Fig-
ure S2). However, CD56dim NK cells in the R565W patients,
which completely lacked GPR56, expressed lower levels of
CD94, indicating maturation. Moreover, the cells expressed
less/no inhibitory KIR2DL1/S1, probably due to allelic variation,
while steady-state expression of cytolytic proteins was un-
changed (granzyme B) or marginally reduced (perforin).
The phenotypic changes found in CD56dim NK cells in the
1693C > T (R565W) siblings raised the possibility that the cyto-
lytic capacity of NK cells in these patients was altered. Indeed,
their NK cells killed K562 cells more efficiently than control cells,
as indicated by enhanced degranulation (CD107a expression)
and induction of apoptosis in the target cells. In addition, target
cell contacts resulted in enhanced production of tumor necrosis
factor (TNF) and interferon (IFN)g by GPR56-deficient NK cells
(Figures 2B and 2C). Thus, lack of GPR56 did not hamper normal
NK-cell development but appeared to enhance their functional
capacity.(B) PBMCswere incubatedwith K562 target cells at an effector/target cell (E/T)
ratio of 1/1 for 5 hr and analyzed by flow cytometry for K562 cell death, NK-cell
degranulation (CD107a), and intracellular production of TNF and IFNg. The
control donor depicted here was analyzed in parallel with the Dutch patients.
(C) Quantification of effector functions analyzed in (B), including additional
control donors.
All data are means ± SEM. *p < 0.05; **p < 0.001; ****p < 0.0001.
See also Figure S2.
NK Cells Downregulate GPR56 upon Cytokine
Stimulation
Upon encounter of virus-infected or -transformed cells, NK cells
downregulate inhibitory receptors to acquire maximal killing ca-
pacity (Pegram et al., 2011). PMA (phorbol-12-myristate-13-ac-
etate) stimulation downregulates ectopic GPR56 in monocytic
U937 cells (Little et al., 2004). In primary NK cells, PMA treatment
resulted in loss of GPR56 at concentrations as low as 1 ng/ml,
which was enhanced by ionomycin (data not shown; Figure 3A;
Figure S3A). With a loss of >60% of cell-surface GPR56 within
10 min and >80% after 2 hr, kinetics resembled the downregula-
tion of CD16 (Figure 3B). Studies with pharmacological inhibitors
confirmed the involvement of protein kinase (PK)C, but not MAP
kinases, in PMA-induced GPR56 downregulation (Figure S3B).
Activation of PKA with forskolin did not affect GPR56 surface
levels (Figure S3A).
aGPCRs are downregulated by internalization or shedding
(Karpus et al., 2013; Langenhan et al., 2013). The dynamin
inhibitor dynasore that prevents internalization and GM6001, a
broad-spectrum matrix metalloproteinase (MMP) inhibitor, syn-
ergistically blocked the downregulation of GPR56 upon PMA
stimulation (Figure 3C). In contrast, downregulation of CD16
upon PMA stimulation was primarily blocked by GM6001 (Fig-
ure S3C). Cleavage of CD16 involves a disintegrin and metallo-
proteinase (ADAM)17 expressed in NK cells (Romee et al.,
2013). Indeed, two ADAM17 inhibitors affected PMA-induced
downregulation of CD16, but not GPR56 (Figure S3C). NK cells
pre-incubated with fluorescently labeled anti-GPR56 or anti-
CD16 monoclonal antibodies (mAbs) on ice and subsequently
treated with PMA for 2 hr had lost 10% of the GPR56-bound
mAb but 70% of the CD16-bound mAb, indicating that
GPR56 was partially endocytosed from the cell surface (Fig-
ure 3D). Moreover, an increase in soluble GPR56 in the medium
was detected after NK-cell stimulation with PMA, which was
abrogated by inhibitors of PKC and MMPs (Figure 3E). Thus,
PKC activation induces downregulation of GPR56 in primary
NK cells via internalization and shedding.
Physiological activation of primary NK cells occurs through
pro-inflammatory cytokines, crosslinking of activating receptors,
or exposure to target cells. To test the effect of cytokines,
we incubated peripheral blood mononuclear cells (PBMCs) for
12–24 hr with IL-2, IL-15, or IL-18, alone or in combination. A
combination of IL-15 and IL-18 reduced GPR56 surface levels
by 40% after 12 hr and by 70% after 24 hr, which was
more efficient compared to the downregulation of CD16 by these
cytokines (Figure 3F). Inhibition of PKC and MMPs blocked the
downregulation of GPR56 and CD16, while blockade of endocy-
tosis with dynasore had no effect (Figure 3G). In line with our
former data, inhibition of ADAM17 blocked the downregulation
of CD16, but not GPR56, leaving the identity of the sheddase
that releases the NTF of GPR56 open (data not shown). Cross-
linking CD16 or exposure to K562 had a small effect on GPR56
surface expression (data not shown). In sum, physiological NK-
cell activation through cytokines causes downregulation of
GPR56 by shedding of the NTF of the receptor.
Notably, activation of primary NK cells downregulates the
expression of Hobit. In PBMCs stimulated for 2 hr with PMA or
for 12–24 hr with cytokines, we found a clear decrease in Hobitand GPR56 transcript levels (Figure 3H), indicating that NK-cell
activation causes downregulation of GPR56, immediately by
shedding of the NTF (discussed earlier) and permanently by ter-
minating gene expression.
GPR56 Controls NK-Cell Effector Functions
To further examine the role of GPR56 in NK-cell function, we
applied ectopic GPR56 expression in NK-92 cells (Peng et al.,
2011). Proper expression and autoproteolytic modification of
the receptor were confirmed by flow cytometry and western
blot analysis, respectively (data not shown). GPR56 overexpres-
sion did not affect cell growth (data not shown). Quantification of
cytolytic proteins revealed a much-reduced expression of
granzyme B, both at the transcript and protein levels, in NK-
92–GPR56 cells (Figures 4A and 4B). In contrast, mRNA and
protein levels of perforin were comparable between NK-92–
Neo and NK-92–GPR56 cells. Moreover, a lower level of TNF,
but not IFNg transcript, was detected in NK-92–GPR56 cells
(Figure 4C). When activated by PMA, NK-92–GPR56 cells pro-
duced less TNF and IFNg than NK-92–Neo cells (Figures 4D
and 4E). These results suggested that forced GPR56 expression
in NK-92 cells negatively regulates the expression of effector
molecules.
Hence, we examined various NK-cell effector activities,
including target cell conjugation and killing, degranulation, and
cytokine production (both intracellular and secreted). GPR56
significantly attenuated cytotoxicity against K562 cells, as indi-
cated by reduced target cell apoptosis, NK-cell degranulation,
and production of TNF and IFNg, when compared with NK-92–
Neo cells (Figures 4F–4H). The compromising effects of GPR56
on NK-cell cytotoxicity were also observed when NK-92–
GPR56 cells were incubated with target cells more resistant to
cell conjugation and killing, such as THP-1 and HeLa cells (Fig-
ure S4). Taken together, we concluded that GPR56 expression
in NK-92 cells attenuates cytotoxic capacity, in accordance
with the findings derived from the primary NK cells of BFPP
patients.
GPR56 Complexes with CD81 to Negatively Regulate
NK-Cell Effector Functions
aGPCRs possess a characteristic bipartite structure (Hamann
et al., 2015). Notably, target cell killing was also reduced in
NK-92 cells expressing cleavage-deficient GPR56, indicating
that autocatalytic processing at the GPS is not a prerequisite
for the inhibitory activity of GPR56 in NK cells (Figure S5). More-
over, we could not confirm interaction with collagen III, the bind-
ing partner of GPR56 on neuronal cells (Luo et al., 2011) (Fig-
ure S6). These findings are in line with reports showing that the
CTF of GPR56 can signal independently of the NTF (Kishore
et al., 2016; Paavola et al., 2011; Yang et al., 2011).
The CTF of GPR56 forms complexes with the tetraspanin pro-
teins CD9 and CD81 at the cell surface (Little et al., 2004). CD81
has been previously reported to inhibit human NK-cell functions
when crosslinked by the major hepatitis C virus (HCV) envelope
protein E2 or anti-CD81 mAbs (Crotta et al., 2002; Tseng and
Klimpel, 2002). Flow-cytometric analysis showed significant
amounts of CD81, but little CD9, in NK-92 cells. Interestingly,
GPR56 overexpression strongly lowered CD81 protein levels,Cell Reports 15, 1757–1770, May 24, 2016 1761
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Figure 3. Inflammatory Cytokines Downregulate GPR56 in Primary NK Cells
PBMCs were stimulated as indicated and analyzed by flow cytometry.
(A) Expression of GPR56 on CD56+CD3 NK cells, stimulated for 6 hr with the indicated amounts of PMA, alone or in combination with ionomycin.
(B) Expression of GPR56 and CD16 on CD56+CD3 NK cells, stimulated for 10 min or 2 hr with 10 ng/ml PMA.
(C) Expression of GPR56 on CD56+CD3 NK cells pre-incubated for 1 hr with 1 mM bisindolylmaleimide I (BIM), 100 mM dynasore (Dyn), 10 mMGM6001 (GM), or
dynasore plus GM6001 (Dyn+GM) before incubation with 10 ng/ml PMA for 2 hr.
(D) Expression of GPR56 and CD16 on CD56+CD3 NK cells, pre-stained with anti-GPR56 or anti-CD16 mAb prior to incubation with 10 ng/ml PMA for 2 hr.
(E) Culture supernatants of PBMCs, pre-incubated for 1 hr with inhibitors before incubation with 10 ng/ml PMA for 2 hr, were analyzed by ELISA for soluble
GPR56.
(F) Expression of GPR56 and CD16 on CD56+CD3 NK cells stimulated for 12 or 24 hr with 500 U/ml IL-2, 10 ng/ml IL-15, 100 ng/ml IL-18, or IL-15 plus IL-18.
Representative flow cytometry plots (left) and quantification of relative geoMFI (right).
(G) Expression of GPR56 and CD16 on CD56+CD3 NK cells pre-incubated with inhibitors and then stimulated for 12 or 24 hr with IL-15 plus IL-18.
(H) Quantification of mRNA expression of Hobit and GPR56 by RT-PCR in PBMCs, incubated with 10 ng/ml PMA for 2 hr or with 10 ng/ml IL-15 plus 100 ng/ml IL-
18 for 12 and 24 hr.
All data are means ± SEM of four independent experiments. *p < 0.05; **p < 0.01; ***p < 0.005.
See also Figure S3.even though RNA transcript levels were reduced only slightly
(Figure S7A), which might be explained by a relatively high turn-
over of GPR56 (and complexed CD81) in NK-92–GPR56 cells
(data not shown). Western blotting indicated that NK-cell activa-1762 Cell Reports 15, 1757–1770, May 24, 2016tion by PMA reduced GPR56 protein levels without affecting
CD81, but interaction with K562 target cells diminished the levels
of both GPR56 and CD81 (Figure S7B). On the other hand, no
significant changes in CD81 protein levels were observed
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Figure 4. GPR56 Expression in NK-92 Cells Reduces Cytotoxic Capacity
Vector-transduced (Neo) and GPR56-overexpressing NK-92 cells were studied.
(A and B) Quantification of mRNA and protein expression of the cytolytic proteins perforin and granzyme B by RT-PCR (A) and flow cytometry (B) in NK-92–Neo
and NK-92–GPR56 cells.
(C and D) Quantification of mRNA and protein expression of the cytokines TNF and IFNg by RT-PCR (C) and flow cytometry (D) in NK-92–Neo and NK-92–GPR56
cells. Protein expression was determined after stimulating cells with 10 nM PMA for 3 and 6 hr.
(E) Secretion of TNF and IFNg by NK-92–Neo and NK-92–GPR56 cells treated with PMA for 1, 3, and 6 hr, measured by ELISA.
(F and G) NK-92 cells were incubated with fluorescently labeled or unlabeled K562 target cell (E/T ratio) for 5 hr and analyzed by flow cytometry for K562 cell
death, NK-cell degranulation (CD107a), and intracellular production of TNF and IFNg. Shown are representative flow cytometry plots (F) and quantification (G).
(H) Secretion of TNF and IFNg by NK-92–Neo and NK-92–GPR56 cells cultured with K562 target cells for 1, 3, and 6 hr, measured by ELISA.
All data are means ± SEM of three independent experiments. ***p < 0.005.
See also Figure S4.when NK-92–Neo cells were activated by PMA or by interaction
with K562 cells (Figure S7B). This result suggested that NK-92–
K562 cell interaction might cause dynamic changes of the
GPR56-CD81 complex on the cell surface.
Indeed, confocal immunofluorescence microscopy revealed
marked redistribution of GPR56 and CD81 in NK-92–GPR56
cells before and after target cell conjugation (Figure 5A). At
steady state, GPR56 and CD81 were largely co-localized and
distributed homogenously on the cell surface. After conjugation
with K562 cells, the levels of both GPR56 and CD81 were
reduced, and the two receptors were clustered mostly to areas
resembling immune synapses, where granzyme B also accumu-
lated (Figure 5A). Such reduction and clustering of CD81 proteinwas not observed in NK-92–Neo cells, suggesting a critical role
for GPR56 in this process.
We confirmed the formation and reduction of GPR56-CD81
complexes in NK-92–K562 co-cultures by immunoprecipitation
(IP) and IP-re-IP experiments (Figure 5B). CD81 was readily
detected in NK-92–GPR56 cell lysate immunoprecipitated
with the anti-GPR56 CG2 mAb. Critically, the amount of
precipitated CD81 was comparable in the lysate of resting and
PMA-activated NK-92–GPR56 cells but much reduced in the
same cells co-cultured with K562 cells. This result was further
verified by IP with the anti-CD81 mAb first, followed by re-IP
with anti-GPR56 CG2 mAb (Figure 5B). These results indicated
that GPR56, indeed, associates with CD81 and that theCell Reports 15, 1757–1770, May 24, 2016 1763
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GPR56-CD81 complexes are diminished upon NK-cell interac-
tion with target cells.
To delineate how the GPR56-CD81 complex modulated NK-
cell function, anti-GPR56 mAbs were used. Crosslinking of
GPR56 by mAb ligation with CG2 and CG5, but not CG3, caused
a rapid dissociation of the GPR56-CD81 complex, as shown by
the IP experiments (Figure 5C; Figure S7C). Importantly, the
cytolytic function and cytokine (TNF and IFNg) secretion of
NK-92–GPR56 and human primary NK cells were greatly
enhanced in the presence of CG2 or CG5 mAbs, whereas the
isotype control Ab and CG3 mAb failed to show such an effect
(Figures 5D–5G). Similarly, shRNA knockdown of CD81 restored
K562 target cell killing by NK-92–GPR56 cells (Figures S7D–
S7F). Finally, we tested whether Gaq/11, which has been
implicated in GPR56-CD81 complex signaling (Little et al.,
2004), is required. Of note, a highly selective Gaq/11/14 inhibitor
(FR900359) (Schrage et al., 2015) did not restore cytolytic activity
in NK-92–GPR56 cells (Figure S7G). We concluded that associ-
ation with CD81, but not Gaq/11, signaling is crucial for the ability
of GPR56 to inhibit NK-cell functions.
DISCUSSION
Here, we describe GPR56 as an inhibitory receptor expressed by
human CD56dim NK cells. CD56dim NK and CD27CD45RA+
T cells are highly reactive cytotoxic effector lymphocytes that
protect the body against harmful viruses and neoplasms. The
effective cytotoxicity displayed by these cells requires a tight
interplay between activating and inhibiting control mechanisms
(Caligiuri, 2008). We previously reported that cytotoxic human
lymphocytes, in contrast to non-cytotoxic lymphoid or myeloid
blood cells, express GPR56 (Peng et al., 2011). This study ex-
tends these findings by showing that GPR56 is induced in
CD56dim NK cells prior to the upregulation of KLRG1 and
CD57, which both appear at later stages of differentiation, asso-
ciated with terminal differentiation (Bjo¨rkstro¨m et al., 2010; Lo-
pez-Verge`s et al., 2010; Voehringer et al., 2002). Of note, long-
lived memory-like NK cells, defined by absent/low expression
of FcRg and PLZF (Lee et al., 2015; Schlums et al., 2015; Zhang
et al., 2013), also expressed GPR56. GPR56 seems to be the
best currently available surrogate surface marker to indicate
cytolytic capacity across all lymphocyte subsets.
The restricted expression of GPR56 by only CD56dim NK (and
CD27CD45RA+ T) cells indicates tight control of its induction
and regulation at the transcript and protein levels. We obtained
evidence that the expression of GPR56 is induced by Hobit, aFigure 5. GPR56-CD81 Complexes at the Immune Synapse Repress C
(A) Surface CD81 and GPR56 and intracellular granzyme B of NK-92–K562 cell c
DAPI staining defined the morphology of nuclei. Scale bars, 10 mm.
(B) 1% CHAPS cell lysate was immunoprecipitated with either anti-GPR56 or an
vealed by immunoblotting (IB) using specific mAbs.
(C) NK-92–GPR56 cells were incubated in the absence (untreated) or presence of 1
using anti-GPR56 mAb. Mouse IgG1 was used as an isotype control. The presen
(D–G) NK-92–GPR56 (D and E) or human primary NK cells (F and G) were incubat
indicated for 2 hr before adding K562 target cells. Percentage of dead target cells
culture (D and F), and amount of TNF and IFNg released into medium during 6 h
Data are representative of three independent experiments; values indicate the m
See also Figures S5, S6, and S7.close relative of Blimp-1, recently discovered by us (van Gisber-
gen et al., 2012). In humans, Hobit is expressed in quiescent
effector NK and T cells, very closely matching the expression
of GPR56 (Vieira Braga et al., 2015). Implying a causal relation-
ship, Hobit knockdown in NK-92 cells prevented induction of
GPR56 upon IL-2 withdrawal, and ectopic Hobit enabled
GPR56 expression in Jurkat T cells. In contrast, manipulating
the expression of Eomes did not affect GPR56 expression,
despite its prominent role in the differentiation and maturation
of effector NK and T cells and, like GPR56, its expression in
developing neurons and relationship with polymicrogyria (Baala
et al., 2007). Thus, based on current evidence, GPR56 is a tran-
scriptional target of Hobit in human NK and T cells.
Of note, the GPR56 locus has 17 transcriptional start sites in
humans, which are targets of different transcription factors,
such as peroxisome proliferator-activated receptor gamma co-
activator 1-alpha 4 (PGC-1a4) in muscle cells (White et al.,
2014) and so-called heptad complex factors in hematopoietic
stem cells (Solaimani Kartalaei et al., 2015), giving rise to a
widespread cellular distribution (Hamann et al., 2015). Hobit
comprises DNA-binding zinc finger domains, which closely
resemble their homologous domains in Blimp-1 (van Gisbergen
et al., 2012; Vieira Braga et al., 2015). In agreement with
the presumed role of Hobit as transcription factor, multiple
copies of the consensus binding sequence for Blimp-1/Hobit
G(T/C)GAAAG(T/C)(G/T) (Doody et al., 2007) are identified in
the 50 region of GPR56 (data not shown).
In mice, peripheral NK and T cells barely express GPR56
(www.immgen.org), which is in line with the absence of Hobit
in these cells (van Gisbergen et al., 2012). Interestingly, resting
murine NK cells are minimally cytotoxic; they contain little gran-
zyme B or perforin protein, whereas the respective mRNAs are
abundant (Fehniger et al., 2007). Cytokine- and virus-induced
activation of murine NK cells results in potent cytotoxicity, asso-
ciated with a strong increase in granzyme B and perforin protein.
It is tempting to speculate that murine NK and T cells do not ex-
press GPR56, due to the different ways they acquire cytotoxic
capacity.
By studying two pairs of BFPP siblings with the recurrent
R565W and C346S mutations in the second extracellular loop
and the GAIN domain, respectively (Piao et al., 2004, 2005),
which both obstruct cell-surface expression of the receptor
(Chiang et al., 2011; Jin et al., 2007), we found that GPR56 is
not required for the development of functionally competent NK
cells. Entirely GPR56-deficient NK cells with the R565W muta-
tion killed K562 cells even more efficiently, indicated byytotoxicity and Cytokine Production of NK Cells
onjugates were sequentially stained and detected using confocal microscopy.
ti-CD81 mAb, as indicated. The presence of GPR56, CD81, and CD9 was re-
0 mg/ml of GPR56mAbs at 37Cor 0C for 15min before lysate collection for IP
ce of CD81 in each immunoprecipitate was revealed by immunoblotting.
ed in plates pre-coated with or without various anti-GPR56 mAbs (10 mg/ml) as
in each sample was quantified by flow-cytometric analysis following 4 hr of co-
r incubation was measured by ELISA (E and G).
ean ± SEM. ***p < 0.005.
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enhanced degranulation, enhanced cytokine secretion, and
enhanced induction of apoptosis in target cells. This observation
provided a clue that GPR56 might regulate NK-cell cytotoxicity,
a finding that we substantiated in NK-92 cells stably overex-
pressing GPR56. NK-92–GPR56 cells contained less granzyme
B and TNF transcripts at resting state and produced less TNF
and IFNg protein upon PMA stimulation. Moreover, their ability
to kill K562 was impaired, as indicated by reduced degranula-
tion, reduced cytokine secretion, and reduced induction of
apoptosis in target cells. Similar results were found in more
killing-resistant THP1 and HeLa cells, altogether demonstrating
that GPR56 inhibits NK-cell cytotoxicity.
Of note, no immune-related clinical phenotype has been re-
ported for BFPP patients. This, however, is not surprising, since
effector functions of NK cells are balanced by activating and
inhibitory signals that are simultaneously delivered to the cells
following the engagement of several distinct families of trans-
membrane receptors (Caligiuri, 2008). GPR56 does not belong
to a receptor family commonly associated with NK-cell regula-
tion, such as Ig-like receptors and C-type lectins (Lanier, 2008;
Pegram et al., 2011). GPR56 is a member of the aGPCR family.
While the functional mechanism of aGPCRs is still poorly under-
stood, evidence accumulates that they are true GPCRs that
regulate wide cellular programs through the action of G proteins
(Hamann et al., 2015; Monk et al., 2015). Indeed, the broad activ-
ity of GPR56 is indicated by its ability to control cytolytic proteins
and pro-inflammatory cytokines, which present the two major
arms of NK-cell activity. Moreover, we previously showed that
GPR56 inhibits spontaneous and SDF-1-stimulated NK-cell
migration (Peng et al., 2011). Studies in other cell types have
implicated roles of GPR56 in the generation and maintenance
of the hematopoietic stem cell pool, cortical development,
male fertility, muscle hypertrophy, and melanoma tumor growth
and progression (Ackerman et al., 2015; Bae et al., 2014; Chen
et al., 2010; Giera et al., 2015; Piao et al., 2004; Saito et al.,
2013; Solaimani Kartalaei et al., 2015; White et al., 2014; Xu
et al., 2006).
Our data indicate that GPR56 executes its inhibitory activity in
concert with the tetraspanin protein CD81. The GPR56-CD81
complex represents an early example of aGPCR in the tetraspa-
nin web, an important membrane protein scaffold for regulating
signal transmission (Little et al., 2004). More recently, the
Drosophila aGPCR Flamingo was shown to interact in cis with
the tetraspanin Van Gogh in the acquisition of planar cell polarity
(Lawrence et al., 2008). The tetraspanin web is well known to
modulate immune signaling, andCD81 has been shown to inhibit
NK-cell functions when crosslinked (Crotta et al., 2002; Tseng
and Klimpel, 2002). Our findings that the GPR56-CD81 complex
on the NK-cell surface was quickly reduced and relocated to
the contact points with the target cells suggested a role in regu-
lating NK-cell activities. Indeed, ligation of GPR56 receptor by
mAbs was found to dissociate the GPR56-CD81 complex, lead-
ing to enhanced NK-cell cytotoxicity and increased cytokine
secretion. Based on these results, we suggest that GPR56
acts as a cell-autonomous NK-cell inhibitory receptor by laterally
crosslinking with CD81. Removing GPR56, hence, resulted in
stronger NK-cell functions, as exemplified by the GPR56-defi-
cient NK cells of BFPP patients as well as NK-92 and primary1766 Cell Reports 15, 1757–1770, May 24, 2016NK cells upon activation by PMA, cytokines, and contact with
target cells.
At present, it is not known exactly how the GPR56-CD81 com-
plex is recruited to the immune synapses upon NK-target cell
conjugation. However, possible mechanisms can be envisioned
based on earlier works. We have previously shown that, while
the majority of the GPR56 NTF-CTF heterodimeric receptor
complex is located in the non-raft region, some of the GPR56
CTF is partitioned to the lipid raft microdomains (Chiang et al.,
2011). Moreover, although lipid rafts and the tetraspanin-en-
riched microdomains (TEMs) are considered distinct membrane
constitutions, co-clustering of lipid rafts and TEMs is possible
upon cell activation or transformation (Krementsov et al., 2010;
Ono, 2010).
Signaling molecules, including Gaq/11, Ga12/13, PKCa, RhoA,
andmTOR, have been linked toGPR56 in different cell types (Ac-
kerman et al., 2015; Giera et al., 2015; Iguchi et al., 2008; Little
et al., 2004; Luo et al., 2011; Paavola et al., 2011; Stoveken
et al., 2015; White et al., 2014). Of interest is the specific associ-
ation with CD81 and Gaq/11, reported by Little et al. (2004), in
which CD81 was critical in promoting/stabilizing the GPR56-
Gaq/11 association. The GPR56-CD81-Gaq/11 complex was
dynamically regulated: anti-CD81 mAb led to the uncoupling of
Gaq/11 from the GPR56-CD81 complex, while cell activation by
PMA dissociated GPR56 from CD81 and Gaq/11, leading to
GPR56 internalization. In the present report, we applied a highly
selective inhibitor of Gaq/11/14, called FR900359 (Schrage et al.,
2015). Of note, FR900359 did not restore cytotoxicity in NK-
92–GPR56 cells. Thus, signaling capacity of the GPR56-CD81
complex in NK cells does not rely on the engagement of Gaq
proteins.
The ability to downregulate inhibitory receptors enables
effector NK and T cells to unfold their full functional capacity.
We found that PMA rapidly and completely downregulates
GPR56 through PKC-mediated shedding and internalization.
Moreover, an inflammatory milieu, created by the potent NK-
cell-activating cytokines IL-15 and IL-18 (Fehniger et al., 1999),
caused PKC-dependent shedding of GPR56. Receptor shed-
ding is a hallmark of aGPCRs and likely relates to the extended
extracellular domains (Hamann et al., 2015). Previous studies
indicate that, in absence of the NTF, the CTF of GPR56 and
other aGPCRs can overtly provide activating signals (Liebscher
et al., 2014; Paavola and Hall, 2012; Paavola et al., 2011, 2014;
Stephenson et al., 2013). GPR56 expression on cytotoxic
lymphocytes will provide an interesting model to determine
the fate and possible activities of an aGPCR upon activation-
mediated release of its NTF and to explore therapeutic possibil-
ities provided by the unique structure of this non-canonical
GPCR.
EXPERIMENTAL PROCEDURES
Donors and Cell Isolation
PBMCs were isolated using a Lymphoprep gradient (Axis-Shield) from fresh
blood of healthy donors and four BFPP patients diagnosed with single muta-
tions in GPR56. Studied were two newly identified Dutch siblings, 46 and 49
years old (1693C > T, R565W), and two previously described Palestinian sib-
lings, 25 and 26 years old (1036T > A, C346S) (Piao et al., 2004). Samples
were obtained under informed consent and in accordance with the ethical
guidelines of the Academic Medical Center, Amsterdam, the Netherlands; the
Radboud University Medical Center, Nijmegen, the Netherlands; and the
Schneider Children’s Medical Center, Petah Tiqva, Israel. CD56+CD3 NK
cells with R99% purity were isolated on a BD FACSAria III Cell Sorter (BD
Biosciences).
Stable Transduction of Cells
Generation of NK-92 cells stably overexpressing GPR56 has been described
previously (Peng et al., 2011). The wild-type and cleavage-deficient mutant
(T383A) of GPR56 were transduced using retroviruses in NK-92 cells. For
gene knockdown, NK-92 cells were transduced using lentiviruses containing
pKLO.1 plasmids with non-target scrambled shRNA (SHC002; sequence
CCGGCAACAAGATGAAGAGCACCAACTC) from Sigma-Aldrich or Eomes
shRNA (TRCN0000013175; target sequence GCCCACTACAATGTGTTCGTA)
and CD81 shRNA (TRCN0000057609; target sequence CCTGCTCTTCGT
CTTCAATTT) from Open Biosystems/GE Healthcare. Cells were transduced
in retronectin (Takara Bio)-coated plates and selected on 2 ng/ml puro-
mycin (Sigma-Aldrich). NK-92 cells expressing pKLO.1 with Hobit shRNA
(TRCN0000162720; CAGAAGAGCTTCACTCAACTT) or Jurkat cells express-
ing LZRS pBM-IRES (internal ribosome entry site)-EGFP with Hobit fragment
were generated previously (Vieira Braga et al., 2015). Transduced Jurkat cells
were sorted to R95% purity on a BD FACSAria III Cell Sorter using GFP
expression as selection marker.
Cytotoxicity Assay
This assay uses 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one)
(DDAO; Invitrogen) to label target cells and 3,30-dihexyloxacarbocyanine io-
dide (DiOC6; Invitrogen) to label live cells. Washed target cells (5 3 106 per
milliliter) were resuspended in 1 nM DDAO/PBS, incubated at 37C for
15 min in the dark, washed, and resuspended in NK-92 medium. PBMCs or
NK-92 stable cells were incubated at various effector/target cell (E/T) ratios
(5/1 to 1/5) with target cells at 37C for 5 hr, followed by the addition of
0.1 mg/ml DiOC6 at 37C for 15 min and analysis by flow cytometry.
Cell Stimulation
For the activation of PKC, PBMCs (13 106 per milliliter) were incubated for 2 hr
in medium plus 10 ng/ml PMA (Sigma-Aldrich). For cytokine stimulation,
PBMCs (13 106 per milliliter) were incubated for 12–24 hr in medium contain-
ing 400 U/ml IL-2, 10 ng/ml IL-15, or 100 ng/ml IL-18 (all R&D Systems),
either alone or in combination, as indicated. For GPR56 Ab crosslinking,
48-well plates (Greiner Bio-One) were coated with PBS containing mouse
IgG, CG2, CG3, or CG5 at 37C for 2 hr followed by overnight coating at
4C. After washing the plates with PBS, NK-92–GPR56 cells or primary
human NK cells (2 3 106 per milliliter) were incubated in coated wells
in complete NK-92 medium. Following 2 hr of crosslinking at 37C, K562 cells
(83 106 per milliliter) were added to wells at an E/T ratio = 2. For cytokine pro-
duction assay, supernatants were collected following 6 hr of stimulation with
K562 cells.
Pharmacological inhibitors were added for 1 hr at 37C prior to stimulation.
Specific inhibitors of PKC (staurosporine, calphostin, bisindolylmaleimide I),
PKB/Akt (Akt1/2 kinase inhibitor), phosphatidylinositol 3-kinase (PI3K;
LY294002), mitogen-activated protein (MAP) kinases (Erk [U0126], JNK
[SP600125], and p38 [SB 203580]), MMPs (GM6001), and dynamin (dynasore)
were all obtained from Sigma-Aldrich. Inhibitors of ADAM10 and ADAM17
(GW) were a gift from GlaxoSmithKline, courtesy of Dr. A. Amour (Stevenage);
a second ADAM17 inhibitor (TNF484) was kindly provided by Dr. U. Neumann
(Novartis). Ga signaling was inhibited using FR900359, a selective inhibitor of
Gaq/11/14 (Schrage et al., 2015).
qPCR
Total RNAwas isolated with the RNeasymini kit (QIAGEN), and cDNAwas syn-
thesized using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher
Scientific). Relative gene expression levels were measured using Fast SYBR
Green Master Mix (Applied Biosystems) on a StepOnePlus system (Applied
Biosystems) with the cycle threshold method. Primers are described in the
Supplemental Experimental Procedures.Flow Cytometry
Staining of extracellular antigens was performed according to standard proce-
dures. Abs are described in the Supplemental Experimental Procedures. For
intracellular antigens, cells were first stained for surface molecules, followed
by fixation with the Foxp3 Transcription Factor Staining Buffer Set (eBio-
science) and incubation with Abs directed against intracellular molecules.
Flow-cytometric analysis was performed on FACSCalibur, FACSCanto II,
and LSRFortessa machines (BD Biosciences), and all data were analyzed
with FlowJo software (Tree Star).
For intracellular cytokine and degranulation staining, PBMCs and stable NK-
92 cells were mixed with K562 in the presence of anti-CD107a and incubated
at 37C for 1 hr in the dark. A mixture of brefeldin A (1 mg/ml; BD Biosciences)
plus monensin (10 mg/ml; BD Biosciences) was then added, and samples were
incubated for a further 5 hr. Cells were labeled with Abs recognizing extracel-
lular antigens, fixed/permeabilized, stained for TNF and IFNg, and examined
by flow cytometry.
ELISA
TNF and IFNg levels in culture supernatants were assessed using DuoSet
ELISA Development Systems from R&D. Soluble GPR56 was quantified as
described previously (Yang et al., 2015). Spectrophotometric analysis was
performed at 450-nm wavelength on a SpectraMax M2 spectrophotometer
(Molecular Devices) using Softmax Pro 5.3 software (Molecular Devices).
Indirect Immunofluorescence
NK-92 cells were conjugated to K562 at a 2/1 ratio, centrifuged at 25 3 g
for 3 min at 4C, and incubated for 30 min at 37C. After conjugation, a total
of 6 3 105 cells were gently resuspended and allowed to adhere to each
poly-D-lysine-coated coverslip (BD BioCoat) at 37C for 30 min, centrifuged
again at 30 3 g for 3 min, and then washed by dipping in DPBS (Invitrogen)
several times at room temperature. Subsequent fixation was carried out in
4% paraformaldehyde/PBS (Sigma-Aldrich) at room temperature for 20 min.
Cells were blocked in PBS containing 2% normal goat serum and 0.5% BSA
and incubated first with mouse anti-CD81mAb (TS81, Abcam) and Alexa Fluor
594-conjugated goat anti-mouse IgG (Invitrogen) and then washed and
blocked again before staining with Alexa Fluor 488-conjugated mouse anti-
GPR56 mAb (CG2). Permeabilization was carried out using 0.5% saponin
(Sigma-Aldrich), and cells were stained subsequently with Alexa Fluor 647-
conjugated anti-granzyme B mAb (GB11, BD Biosciences). Coverslips were
mounted using ProLong Gold (with DAPI) mounting medium (Invitrogen).
Confocal images were captured on a Zeiss LSM 510 META confocal micro-
scope (Carl Zeiss), using a 643 oil immersion objective. Single images were
captured with an optical thickness of 1.5 mm. Analysis was performed using
LSM510 META software (Carl Zeiss).
IP
Cells were lysed in a 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-
sulfonate (CHAPS) buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl,
5 mM MgCl2, 5% glycerol, and protease inhibitors including 1 mM sodium or-
thovanadate, 10 mg/ml aprotinin, 5 mM levamisole, 1 mM 4-(2-aminomethyl)
benzenesulfonyl fluoride hydrochloride (AEBSF), and cOmplete protease inhib-
itor from Roche Diagnostics. Lysates were extracted on an end-over-end rota-
tor at 4C for 3 hr and collected after removing insoluble fraction by centrifuga-
tion at 12,000 rpm for 25 min at 4C. Supernatants were pre-cleared with
protein G sepharose (Sigma-Aldrich) for at least 1 hr at 4C on a rotator or,
for lysates collected from Ab-pre-treated cells, with mouse IgG conjugated to
agarose (A0919; Sigma-Aldrich). Specific mAbs (4 mg) were then mixed with
pre-cleared lysates (5 3 106 cell equivalents) and incubated on ice for 2 hr
before adding 20 ml of 1:1 diluted protein G sepharose beads. Immunoprecip-
itates were then collected overnight at 4C on a rotator, washed five times
with cold 1% CHAPS lysis buffer, eluted with 23 Laemmli buffer at 95C for
8min, and resolved on an 8% (for GPR56) or on a 12% (for CD81 andCD9) non-
reduced SDS-PAGE. For re-IP, CD81-associated molecules were eluted with
1% Triton X-100 lysis buffer following anti-CD81 (clone TS81) IP. Eluates
were then subjected to a second IP using anti-GPR56 (clone CG2) mAb. Immu-
noprecipitates were analyzed by immunoblotting using anti-GPR56 (clone
CG4), anti-CD81 (clone 5A6), and anti-CD9 (clone MM2/57) mAbs.Cell Reports 15, 1757–1770, May 24, 2016 1767
Statistics
All results were analyzed by Excel (Microsoft) or GraphPad Prism (GraphPad
Software) and expressed as means ± SEM. A Student’s t test was used to
determine p values. Significance was set at p < 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2016.04.053.
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